Sir, The Klebsiella pneumoniae carbapenemase (KPC) is a class A β-lactamase that confers resistance to virtually all β-lactams including carbapenems. Initially reported in the USA in a Klebsiella isolate in 1996, KPC-producing K. pneumoniae have been responsible for large nosocomial outbreaks in the USA, Israel and Greece where these isolates are now endemic in hospitals.1 The rapid dissemination of KPC enzymes among and across different enterobacterial species is likely to be due to the localization of blaKPC genes on transferable broad host range plasmids and their association with a transposon,2 but is also linked with a disseminated international clone of KPC-producing K. pneumoniae isolates of sequence type (ST) 258.3,4 Here we report on the first three cases of KPC-2-producing ST258 K. pneumoniae that were detected in Belgium, subsequent to the transfer of patients from three Greek hospitals. In 2009, a patient with high-grade bladder neoplasm with pelvic metastases was transferred from a hospital in Greece to St-Pierre University Hospital in Brussels. Six weeks later, a patient with severe trauma was transferred from another hospital in the same region of Greece to the intensive care unit (ICU) of the same Brussels hospital. Finally, a few days later, the third polytrauma patient was transferred from the ICU of a hospital in Rhodes to the ICU of Erasme University Hospital in Brussels.
No takes yet. Share an insight, caveat, or question.
Bogaerts et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: